hinge region, peripheral subunit-binding domain (S), and third hinge region (residues 128−330); the L1L2S tridomain, which comprises L1, L2, both hinge regions, and the subunit-binding domain (S, residues 1−330); the L3S' didomain of E3BP (residues 1−230), all expressed from pET28b in E. coli BL21 (DE3) cells, and purified using Ni Sepharose 6 Fast Flow column 10 .
Two singly substituted variants of L1L2S were also used in this study: L1L2S-ML1 with the Lys46Ala substitution in the outer L1 domain, hence the inner L2 domain available for lipoylation, and L1L2S-ML2 (Lys173Ala substitution in the inner L2 domain, hence the outer L1 domain available for lipoylation). Recombinant E3 was overexpressed in E. coli cells and was purified as described earlier 11 .
Recombinant rat PDK1, rat PDK2, human PDK3 and rat PDK4 were overexpressed and purified individually in E. coli BL21(DE3) cells transformed with pPDK expression vector using protocols reported in the literature 6, [12] [13] [14] . According to the literature, the amino acid sequence of human PDK1 has 93% identity with rat PDK1, while human PDK2 has 96% identity with rat PDK2 15 . Human PDK3 shares 68% and 67% identity with human PDK1 and human PDK2, respectively 15 . confirmed by FT-MS using the electrospray ionization sampling method.
Construction of Plasmid and Expression and

Reaction of DANS-As with the Source of the Lipoyl Domains (L1, L2S, L1L2S, L1L2S-ML1,
L1L2S-ML2 and L3S').
First, the lipoylated source of the lipoyl domain (50 µM) in 30 mM KH 2 PO 4 (pH 7.5) containing 0.15 M NaCl (sample buffer) was reduced by incubation for 5 min with TCEP (100 µM) at room temperature, resulting in fully reduced lipoyl domains according to FT-MS. Second, the reduced lipoyl domains were reacted with 150 µM DANS-As for 2 h at room temperature, leading to chemically modified lipoyl domains. The excess of TCEP and DANS-As were removed from the reaction mixture with a 10K MWCO centrifugal filter unit (Vivaspin 500, 10K MWCO). Modification of the lipoyl domains was confirmed by FT-MS.
Enzyme Activity Measurements. Overall PDC activity was measured by assembly of E1 with recombinant E2·E3BP core and recombinant E3. The E1 component (1.0 µg) was preincubated in the cuvette with a mixture of E2·E3BP core and E3 at a mass ratio of 1:3:3 for 1 min at 37 o C Aliquots (1 µg of E1) were withdrawn at the indicated times and added to a 1 mL cuvette containing all components for PDC assay. PDC was allowed to assemble for 1 min at 37 o C and the reaction was started by addition of pyruvate and CoA as above. PDK4 n/a n/a n/a n/a n/a n/a 0.008 (n/a) 0.007 (n/a) a The half time of PDC inactivation (t 1/2, min ) is presented in the parentheses. b Time course of the fraction of the remaining PDC activity was fit to a single exponential.
c n/a, data not available because no inactivation was detected.
